Industry: Health Care – Biotechnology: Pharmaceutical Preparations
Stock Symbol: CTOR – NASDAQ
Animal Usage: Animal Testing
Citius Oncology Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
Supporting Evidence:
The company confirms in corporate disclosures that it utilizes animal subjects for product testing.
“Citius is conducting a proof-of-concept study to test the safety and efficacy of a novel potent iPSC induced MSCs ( i-MSCs) in a clinically relevant sheep model of sepsis-induced ARDS. Interim results show that animals receiving i-MSCs demonstrated clear improvement over control animals with improved oxygenation, less systemic shock and reduced lung vascular injury.” Read the article for more details
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Company Website: https://www.citiusonc.com